

1
2 ***What is a furin cleavage site, why is it important,***
3 ***and how might this have arisen in SARS-CoV-2?***
4
5

6
7 Neil L Harrison¹, Jeffrey D Sachs²
8

9 ¹Columbia University, Department of Anesthesiology, New York, NY, USA

10 ²Columbia University, Sustainability Institute, New York, NY, USA
11

12
13
14 *Corresponding authors: sachs@ei.columbia.edu, nh2298@columbia.edu
15

16 **Keywords**

17 SARS-CoV-2, furin cleavage site, furin
18
19

20 **Summary**
21

22 There is no consensus among scientists on the origin of SARS-CoV-2. One
23 aspect of the virus that has been much discussed is the so-called “furin
24 cleavage site” (FCS). Here we explain the structure and function of the
25 FCS and its significance in SARS-CoV-2. The existing data suggest that
26 the FCS of SARS-CoV-2, which remains unique among the hundreds of
27 *sarbecoviruses* sampled from bats around the world, is fully functional and
28 is consistent with the properties of FCS in many other substrates of this
29 protease. Three possible routes have been proposed for how the FCS
30 appeared in SARS-CoV-2: natural recombination, serial passage in cell
31 culture or in an animal host and laboratory insertion via gene engineering.
32 Here we review the merits and limitations of each proposal. All three
33 proposals are limited by the absence to date of an immediate precursor
34 virus. We renew our call that virus databases, lab notebooks and electronic
35 communications be made available for independent scrutiny as part of a
36 bipartisan investigation into the origins of COVID-19.

37 The “furin cleavage site” (FCS), is an important feature of the Spike protein
38 of the SARS-CoV-2 virus (Figure 1a). The FCS is present in the novel virus
39 SARS-CoV-2, but is absent in SARS-CoV-1 (Figure 1b) and in all other
40 members of the group of most closely related viruses, the subgenus
41 sarbecovirus (Figure 1c) (Coutard et al., 2020; Hoffmann et al., 2020b;
42 Temmam et al., 2023), which now includes several hundred viruses, almost
43 all of which were found in bats around the world.

44
45 A great deal has been written and said about the FCS in scientific journals,
46 in mainstream news outlets and on social media media, yet there is still
47 considerable confusion about the structure, function, and importance of the
48 FCS in SARS-CoV-2. We aim to clarify key issues here.

49
50 The FCS is the site at the S1-S2 junction where the Spike protein of the
51 virus is cut by *furin*, an enzyme that is expressed in most human cells
52 (Thomas, 2002). This process is known as proteolysis. Processing of the
53 Spike protein by a combination of the two enzymes, furin and TMPRSS2
54 (Hoffmann et al., 2020a, Ou et al., 2021) (**Figure 2a**) is critical to the entry
55 of SARS-CoV-2 into cells in the lower respiratory tract (Coutard et al.,
56 2020) to infect the human lung - as well as for the transmission and
57 pathogenicity of the virus (Johnson et al., 2021, Peacock et al., 2021).

58
59 The importance of furin cleavage for viral entry has been known since the
60 earliest work on *Sindbis* virus (Klimstra et al., 1999) but this is not a
61 universal feature for all viruses. For example, the replication of respiratory
62 syncytial virus (RSV) does not require furin (Zimmer et al., 2002). We
63 thought it a good idea to outline here some of the basic biology of furin and
64 the FCS, and to explain why this become so important to the study of how
65 the virus enters cells, as well as to discussions of the origins of the virus.

66 **What is furin?**

67
68 Furin is an enzyme that cuts proteins, i.e. it is a *protease*. To be more
69 specific, it is a member of a group called *proprotein convertases*, which is to
70 say it is an enzyme that is responsible for processing larger proteins into
71 their active final form (Seidah et al., 1998; Seidah & Prat, 2012).

72 Processing of larger precursors is especially important in endocrinology,
73 with many hormones such as insulin being derived by proteolysis of larger
74 protein precursors. Furin itself is produced by auto-proteolysis from a
75 precursor protein (Thomas, 2012).

76

77 Furin was first identified and originally designated as PACE, and the gene
78 was cloned in 1990 (Bresnahan et al., 1990). Unlike other proteases such
79 as TMPRSS2 that are found at the cell surface (Meng et al., 2020), furin is
80 mainly located inside the cell, specifically inside membrane-bound
81 organelles (**Figure 2b**), being synthesized on the endoplasmic reticulum
82 and then is modified in the presence of Ca^{2+} , moving through the ER-Golgi
83 intermediate complex (ER-GIC) to the trans-Golgi network (TGN) where the
84 mature form of the protein is stabilized at low pH (Thomas, 2002).

85

86 Once in the TGN, furin modifies proteins that have already been
87 synthesized, including those being packaged into vesicles for export to the
88 plasma membrane (**Figure 2b**). In the process, furin itself appears on the
89 cell surface, from where it is then recycled into endocytic vesicles (Molloy
90 et al., 1994). Viruses, including coronaviruses, make use of this cellular
91 sorting machinery to facilitate the manufacture of membrane-bound protein,
92 forming new virus particles. The Spike protein of SARS-CoV-2 is one
93 example, and it can be cleaved by furin inside the infected cell before being
94 packaged into newly synthesized virus containing other viral components.
95 These are essential steps in the process by which new virions exit the cell.

96

97 **What exactly is a furin cleavage site?**

98 Furin works by “cutting” the peptide strand of a precursor protein at one or
99 more locations, specifically by *catalyzing the hydrolysis of a specific*
100 *peptide bond*, typically between an arginine residue and its immediate
101 neighbour, which is variable but is typically a smaller (serine or valine)
102 residue (6). The hydrolysis of the peptide bond at $\text{R}\downarrow\text{X}$ is most efficient
103 when a specific *furin recognition sequence* is present, which is enriched in
104 basic amino acid residues (R/K). The typical furin cleavage site contains at
105 least 2 basic residues, separated by 2 amino acids, **RXXR** (this is RRAR in
106 SARS-CoV-2; **Figure 1a**), but there are exceptions to this rule. This
107 minimal consensus recognition sequence is what is usually referred to as a
108 “*furin cleavage site*”, although the proteolysis “cleavage” actually takes
109 place very specifically at what is termed the “scissile bond” ($\text{R}\downarrow\text{X}$), at the
110 C-terminal end of the RXXR recognition sequence.

111

112 Note that proteins can also be susceptible to proteolysis by other enzymes
113 found outside cells, such as trypsin and cathepsin B etc., and that the
114 importance of the specific furin recognition sequence is to enhance the
115 efficiency of proteolysis by one specific protease, furin, which is expressed
116 in most cells. There are examples of proteins that contain multiple FCS, so

117 that the protein is synthesized in its inactive form, and can then be
118 activated by the removal of an intervening auto-inhibitory domain, as
119 occurs with the epithelial sodium channel, ENaC (Kota et al., 2018) and in
120 the case of furin itself (Thomas, 2002). It is common for viral Spike proteins
121 to contain more than one FCS (Millet et al., 2014).

122

123 **What characterizes a furin cleavage site?**

124 Like all enzymes, furin has a well-characterized *catalytic domain*, which is
125 defined as the part of the enzyme that makes contact with the protein
126 substrate. This is where the chemical reaction “hydrolysis” occurs (Henrich
127 et al., 2003) and this is located within a hydrophilic region of the protein.
128 The structure of furin has been solved and the catalytic domain lies within a
129 substrate-exposed part of the furin structure. The substrate protein binds to
130 furin in a manner that activates the enzyme (Dahms et al., 2016), in an
131 example of “induced fit”, interacting not just via the short furin recognition
132 sequence but over a more extended surface. The furin interaction domain
133 of the substrate is recognized to be part of an extended FCS strand that is
134 typically of around 20 amino acids in length (Tian, 2009), that stabilizes the
135 cleavage site by making close contacts within the catalytic domain of furin.

136

137 An extensive analysis of over a hundred proteins that are cleaved by furin
138 has shown that the furin recognition sequence has certain conserved
139 characteristics. The full-length furin cleavage site motif is typically
140 comprised of about 20 residues, here annotated P14-P6' (Tian, 2009)
141 (**Figure 3a**). The FCS residues are numbered relative to the site (the
142 scissile bond) where the polypeptide is cut, and thus the arginine at 685 in
143 the SARS-CoV-2 spike protein is designated as the “P1” position (**Figure**
144 **3b**), with the serine being the “P'1 position”. The other arginines in the
145 RRAR sequence are thus in the “P3” and “P4” positions, and in the case of
146 SARS-CoV-2, a proline occupies the “P5” position, a feature that has been
147 noted by several commentators (Holmes et al., 2021, Garry, 2022).

148

149 Specific physical properties such as volume, charge, and hydrophilicity are
150 required at specific positions in order to optimize the cleavage of substrate.
151 The furin cleavage site motif can be divided into two parts: a core region of
152 8 amino acids, (positions P6-P2') packed inside the furin binding pocket,
153 and two flanking regions (**Figure 3a**) that are both solvent-accessible and
154 located outside the furin binding pocket – one of 8 polar amino acids,
155 (positions P7–P14), and another of 4 small amino acids, (positions P3'-
156 P6'). In the case of the SARS-CoV-2 Spike protein, some of the interactions

157 with the catalytic domain of furin are thought to be made in the core, with
158 the flanking regions providing stabilizing interactions (Venkadari, 2020).
159 More recent work has shown that the flanking regions can also be very
160 important, as in the case of the QTQTN motif (P7-P11) of the SARS-CoV-2
161 Spike (**Figure 3b**), which has been shown to be important for SARS-CoV-2
162 pathogenesis (Vu et al., 2022) as well as being highly antigenic (Haynes et
163 al., 2021).

164
165 The S1/S2 junction of the SARS-CoV-1 Spike lacks the FCS but forms a
166 short solvent-exposed loop (**Figure 4a**) and this loop is further extended in
167 SARS-CoV-2 (**Figure 4a, 4b**) due to the PRRA insert (Jaimes et al., 2020),
168 exposing the FCS for proteolysis. The intricate details of the SARS-CoV-2
169 FCS are only truly revealed in an elegant study of its interaction with the
170 catalytic domain of furin (**Figure 5a**) (Venkadari, 2020). The basic residues
171 within the polybasic RXXR sequence of a typical FCS make electrostatic
172 contacts with negatively charged residues in the catalytic domain of furin
173 (Venkadari, 2020) (**Figure 5b**), while in the case of SARS-CoV-2, the “P5”
174 residue is modeled with the proline side chain oriented away from the
175 catalytic domain (**Figure 5c**) so that there is no steric or electrostatic
176 hindrance. In fact, a variety of smaller amino acids can be tolerated at this
177 P5 position of FCS (Tian, 2009); there is thus no thermodynamic or steric
178 “prohibition” against a proline residue being located adjacent to the core
179 recognition sequence.

180
181 It follows from this survey of many FCS domains that a proline at the P5
182 position is neither unexpected nor unusual, contrary to some commentary
183 (Garry, 2022). Indeed, this point is emphasized by the fact that the Spike of
184 the MERS virus also has a proline at this P5 position (Millet et al., 2014,
185 Garry, 2022), although opinions may differ on whether the FCS of MERS is
186 itself fully functional (Millet et al., 2014).

187 188 **The furin cleavage site of SARS-CoV-2 is fully functional**

189 The argument has been advanced that the FCS in SARS-CoV-2 is “sub-
190 optimal”. This claim seems to be based on computer algorithms that predict
191 the functionality of FCS sequences. Two such algorithms are now in
192 widespread use (e.g. Duckert et al., 2004). Yet these algorithms are known
193 to give “false negatives”, i.e. the failure to predict a fully functional FCS.

194
195 One example of a predicted “sub-optimal” FCS (Holmes et al., 2021) is the
196 RRAR↓SVAS sequence of SARS-CoV-2 itself. Although this FCS scores

197 lower than others according to prediction algorithms, it is fully and efficiently
198 cleaved when cells are infected with SARS-CoV-2 (Hoffmann et al., 2020b,
199 **Figure 6a**) or with pseudoviruses expressing the SARS-CoV-2 Spike
200 protein (Walls et al., 2020; Peacock et al., 2021) (**Figure 6b**), in contrast to
201 the SARS-CoV-1 Spike (**Figure 6c**) and this efficient proteolysis is
202 abolished by deletion of the PRRA sequence (**Figure 6c**). It is worth noting
203 that an identical FCS sequence is found in the α subunit of human ENaC
204 (Anand et al., 2020) and that the ENaC α protein from mouse and rat is
205 also completely and efficiently cleaved by furin in epithelial cells (Hughey et
206 al., 2004, Kota et al., 2018).

207
208 Two algorithms predict that the FCS of SARS-CoV-2 is not “ideal”, and this
209 led several scientists to speculate that the FCS was “sub-optimal” (Holmes
210 et al., 2021). Of course, the efficient proteolysis described above (**Figure**
211 **6a-d**) and the high human-to-human transmissibility of SARS-CoV-2 (R_0
212 $\sim 2-3$ for the original Wuhan-1 virus) would seem to argue otherwise.

213
214 Because of the assertions that the FCS is “sub-optimal”, one might expect
215 to find viral variants that show FCS mutations enhanced proteolysis. In fact,
216 the RRAR (P4-P1) core sequence has remained remarkably stable (Wolf et
217 al., 2022), suggesting that such mutations would confer no evolutionary
218 advantage. A variety of natural polymorphisms (point mutations) within the
219 extended FCS region have now been tested (Arora et al., 2022), and these
220 mutations actually *resulted in a modest loss of proteolysis efficiency*
221 relative to the original FCS (**Figure 6d**). While it has been suggested that
222 the efficiency of proteolysis of the SARS-CoV-2 Spike protein would be
223 further enhanced by mutation at the P5 residue, including the naturally
224 observed mutations P681R and P681H (Peacock et al., 2021b), it is now
225 clear that the experimental data do not in fact support this. In addition, it
226 has been shown that the FCS of the original SARS-CoV-2 Spike protein
227 can be imported into the SARS-CoV-1 Spike by engineering and that the
228 resulting mutant Spike is then fully and efficiently cleaved by furin, in cells
229 experimentally infected via a pseudovirus (Winstone et al., 2021). There is
230 thus no convincing evidence that the FCS of SARS-CoV-2 is sub-optimal.

231 232 **Insights from Structural Biology: studies of the Spike protein**

233 Elegant work done following the emergence of SARS-CoV-1 had shown
234 that this virus uses the human membrane protein angiotensin converting
235 enzyme-2 (ACE2) as its primary receptor on human cells (Li et al, 2005).
236 Studies of SARS-CoV-2 confirmed that the newer virus also uses human

237 ACE2 as its primary receptor on susceptible cells (Shang et al., 2020;
238 Hoffmann et al., 2020a) and that the Spike protein forms a trimeric
239 assembly that binds with high affinity to its receptor (Walls et al., 2020).
240 The trimer exists in multiple conformational states and binds to hACE2 with
241 one S^B domain of the Spike protein in the open conformation (Wrapp et al.,
242 2020 Walls et al., 2020). In one especially insightful experiment (Wrobel et
243 al., 2020), a comparison was made between the Spike proteins of SARS-
244 CoV-2 and a close relative termed RaTG13, which is known to infect bats
245 but is not thought to infect humans. Firstly, it was found that there were
246 small but significant differences between the structures of the receptor
247 binding domains (RBD) of the Spike proteins of these two viruses (**Figure**
248 **7a**). Secondly, it was noted that the Spike of RaTG13 binds very weakly to
249 hACE2, with as much as 1000 times lower affinity (**Figure 7b**), largely due
250 to steric constraints in the interaction between the RBD of the Spike and
251 hACE2 (**Figure 7b**). Crucially, these and other authors noted that cleavage
252 by furin destabilized the “closed” conformation of the Spike protein trimer
253 and hence promoted the “open” conformation, exposing the RBD that is
254 necessary for the binding of the Spike to hACE2. The lack of FCS in the
255 RaTG13 limits the Spike cleavage by proteolysis and stabilized the Spike in
256 the closed conformation associated with low affinity binding to hACE2
257 (Wrobel et al, 2020).

258

259 **The importance of FCS for viral transmission**

260 The importance of FCS for viral entry and transmissibility has been known
261 for some time. Extensive work has been performed in laboratories around
262 the world to insert FCS via genetic engineering into pathogenic viruses,
263 including influenza viruses (Schrauwen et al., 2011) and coronaviruses
264 such as SARS-CoV-1 (Millet et al., 2015) and the porcine epidemic
265 diarrhea virus, PEDV (Li et al., 2015). It should be pointed out that the vast
266 majority of this work was done in the context of *pseudovirus* experiments,
267 using an innocuous virus as a backbone, so that the chance of producing a
268 highly pathogenic virus with increased transmissibility escaping from a
269 laboratory was minimized (Belouzard et al., 2009). Work done in this format
270 is therefore considered safe and does not constitute what is known as
271 “Gain-of-Function” (GoF) research. In at least one case (the example given
272 above of PEDV), this type of work created a replication-competent novel
273 recombinant virus (Li et al., 2015), showing that engineering of functional
274 infectious viruses in this region is neither implausible nor novel.

275

276

277 **Research on the FCS in SARS-like viruses since SARS-CoV-1**

278 There has obviously been a long-standing interest among coronavirus
279 researchers in the role of spike protein proteolysis in enhancing viral entry.
280 Since the original epidemic of SARS and the identification of SARS-CoV-1
281 as a coronavirus that uses ACE2 as its receptor on epithelial cells, much
282 attention has been devoted to the study of the SARS-CoV-1 Spike protein
283 (Li et al., 2005), and FCS has been inserted into the spike protein of this
284 virus on multiple occasions (Belouzard et al., 2009; Millet et al., 2015).

285
286 Work on proteolysis as a determinant of viral entry was recently extended
287 to a range of viruses that include bat coronaviruses from the *sarbecovirus*
288 group (Menachery et al., 2020) some of which have been suggested to
289 show the potential for emergence (Menachery et al., 2015). Such work is
290 sometimes done under conditions of limited containment (BSL-2) because
291 of the perception that these bat *sarbecoviruses* lack pathogenic potential.
292 Work done on these bat viruses has proliferated, and is widely considered
293 to be a “grey area” that constitutes Gain-of-Function research of concern
294 (GoFRoC), since chimeric viruses of unknown function are created and the
295 pathogenicity of the resulting virus cannot be predicted. Laboratory
296 experiments using pseudoviruses showed that infection of lung cells by
297 SARS-CoV-2 and transmissibility between ferrets is strongly inhibited by
298 removal of the PRRA sequence (Peacock et al., 2021), and complementary
299 work in pseudovirus experiments confirmed that insertion of the PRRA
300 sequence into the Spike protein of SARS-CoV-1 confers high furin
301 sensitivity (Winstone et al., 2021) and enhances viral entry into cells.

302
303 **The possible origins of the FCS in SARS-CoV-2**

304 A combination of efficient human-to-human transmission with significant
305 pathogenicity is one of the hallmarks of a pathogen with pandemic potential
306 (PPP). In fact, the combination of factors that made SARS-CoV-2 a
307 pandemic virus involves a combination of its high affinity for human ACE2,
308 its processing by furin and TMPRSS2 (Essalmani et al., 2022) as well as its
309 ability to down-regulate the “innate immune response” in humans that is
310 mediated by interferons (Winstone et al., 2021), perhaps via one or more of
311 the “accessory” proteins of the virus, encoded by 3'-open reading frames
312 (Orf). All of these features of the virus may have arisen naturally, but the
313 unique nature of the FCS in SARS-CoV-2 among the SARS-related bat
314 viruses of the *sarbecovirus* clade (Coutard et al., 2020, Hoffmann et al.,
315 2020b) is quite remarkable (**Figure 1c**) and has given rise to speculation
316 about a possible anthropogenic origin (Chan and Zhan, 2022). Intensive

317 study on bats from around the world (Temmam et al., 2022, Sander et al.,
318 2022; Apaa et al., 2023) has led to the identification of hundreds of novel
319 sarbecoviruses, but not a single virus other than SARS-CoV-2 has been
320 shown to have an FCS.

321
322 FCS sequences do, of course, exist in many of the common coronaviruses
323 that infect humans and other animals (Wu and Zhao, 2021) including the
324 endemic “common cold” viruses, OC43 and HKU-1, which are not
325 pathogenic in healthy, immunocompetent individuals. The FCS may
326 contribute to the high transmissibility of these respiratory viruses. In
327 contrast, the sarbecoviruses are primarily *enteric* viruses in the bat and
328 therefore remain confined to a limited host range. These viruses (BANAL-
329 20-236 for example) efficiently infect human intestinal epithelial cells but do
330 not infect cells of the mammalian respiratory tract (Temmam et al., 2023).
331 The pathogenic viruses such as SARS-CoV-1 and SARS-CoV-2 are
332 obviously an important exception to this rule. In this context, it is worth
333 noting again that the SARS-CoV-1 virus, although highly pathogenic and
334 capable of human-to-human transmission, lacks the FCS and this feature
335 may have ultimately limited its pandemic potential. Experimental work
336 undertaken to investigate the significance of the FCS for pathogenesis has
337 included multiple examples of insertion of FCS-type sequences into SARS-
338 CoV-1 spike, in the context of a pseudovirus (Watanabe et al., 2008;
339 Belouzard et al., 2009, Winstone et al., 2021). For this reason, there is little
340 question concerning the technical feasibility of such an insertion.

341
342 **Did the FCS of SARS-CoV-2 Evolve Naturally via Recombination?**
343 Sequence alignments suggest that the possibility that FCS can evolve in
344 sarbecoviruses via a series of individual point mutations is low. Most of the
345 viruses are insufficiently similar to permit a convincing alignment in the
346 S1/S2 region (Holmes et al., 2021; Sander et al., 2022). Only the most
347 highly similar viruses like RaTG13 and BANAL-20-52 provide the
348 opportunity to align the amino acid or RNA sequences with SARS-CoV-2 in
349 this region.

350
351 Well-articulated (but as yet unproven) arguments have been advanced that
352 invoke processes of natural recombination in the acquisition of the FCS by
353 SARS-CoV-2. Most notably, proposals from evolutionary biologists (Sander
354 et al., 2022) and experimental virologists (Gallaher, 2020) invoke the
355 process of “copy-choice” recombination. Such proposals are plausible but
356 are not at this point supported by experimental evidence. Among the main

357 criticisms of these proposals has been the lack of a natural virus that is a
358 sufficiently good match to the SARS-CoV-2 RNA sequence to have served
359 as the immediate precursor for the proposed recombination event (Chan
360 and Zhao, 2022). Even the closely related virus RaTG13, or the viruses
361 identified in bats from Laos are not sufficiently similar at the RNA level to
362 have served as the immediate ancestor to SARS-CoV-2 (Gallaher, 2020;
363 Temmam et al., 2022). Less well-articulated arguments in favor of a natural
364 origin of the FCS have been advanced (Garry, 2022) and clearly refuted
365 (Harrison and Sachs, 2022b).

366

367 **Did the FCS of SARS-CoV-2 Arise During Serial Passage?**

368 An alternate explanation for the presence of the FCS in SARS-CoV-2 and
369 its apparent adaptation to human cells, is that it might have arisen during
370 the passage of a precursor virus in the laboratory, either during work done
371 in human cells grown in cell culture or during serial passage in animal
372 models such as humanized mice. Neither of these possibilities can be ruled
373 out, but some evidence has accumulated to suggest that this may not have
374 taken place. A bovine coronavirus was reported to have acquired a 12nt
375 insert encoding the four amino acids SRRR during passage in human cells
376 (Borucki et al., 2013), but on closer inspection of the data it emerged that
377 this was not the case, as the variant carrying the insert was already present
378 and had been selected for during passage, presumably because it
379 conferred an advantage to the virus when grown in human cells.

380

381 An interesting and more recent study of serial passage looked at the bat
382 virus BANAL-20-236, a *sarbecovirus* that was sampled from bats in Laos
383 (Temmam et al., 2022) and is one of the closest known relatives of SARS-
384 CoV-2. The sequence of the Spike protein around the S1/S2 junction is a
385 close (but inexact) match to the sequence present in SARS-CoV-2.
386 BANAL-20-236 is not able to infect human airway epithelial cells, but by
387 growing this virus in human intestinal cells in culture, it was possible to
388 propagate the virus and to look for evidence of adaptation to human cells.
389 Although evidence was found for point mutations in the RBD during
390 passage in cell culture, a FCS did not emerge from these experiments.
391 Serial passage experiments performed with BANAL-20-236 in humanized
392 mice produced similar results (Temmam et al., 2023). These results do not
393 support the popular theory that the FCS arose during serial passage in
394 culture, but are consistent with ideas that have been proposed regarding
395 the adaptation of the RBD in a laboratory setting (Sirotkin & Sirotkin, 2020).

396

398 **Was the FCS of SARS-CoV-2 Engineered?**

399 It is clear from the DEFUSE grant proposal released in 2021 that the UNC-
400 WIV-EHA group was planning to extend their ongoing studies on
401 proteolysis (Menachery et al., 2020) as a factor in controlling viral entry,
402 and that they aimed to do so by identifying novel FCS sequences and
403 inserting these into newly identified coronaviruses (Lerner, 2021), and this
404 proposal might obviously include work on unreported viruses that have not
405 been disclosed. As with the arguments for natural origin, the main criticism
406 of the idea that lab manipulation was involved is that the precursor virus
407 (the “template”) necessary for such engineering experiments has not been
408 identified. It is worth noting here that BANAL-20-52, BANAL-20-236 and
409 RaTG13, although the closest relatives to SARS-CoV-2, *are simply too*
410 *different at the nucleotide level* to have served as the precursor for either
411 route of origin (**Figure 8a**).

412

413 The experiments proposed by EHA and their partners in DEFUSE would
414 seem to represent a logical extension of the work of many virologists, in
415 particular the work done on proteolysis as a factor determining host range,
416 and their long-standing interest in the FCS as a critical determinant of viral
417 entry. A lack of transparency regarding this research has amplified
418 concerns that the FCS of the virus might have a laboratory origin (Segreto
419 and Deigin, 2020; Chan and Zhao, 2022). Insertion of the FCS by
420 engineering is technically very simple to achieve and has already been
421 performed many times, for example, with SARS-CoV-1 in pseudovirus
422 experiments (Watanabe et al., 2008; Belouazard et al., 2009; Winstone et
423 al., 2021).

424

425 An unusual *BsaX I* restriction site is found in SARS-CoV-2, bracketing the
426 P2-P12 residues, and contained within the extended FCS (**Figure 8b**). This
427 interesting observation, made by many observers, is consistent with the
428 idea that the FCS could have been inserted in a lab. In fact, the much-
429 maligned proline (P681) found at the P5 position, adjacent to RRAR, is
430 both consistent with, and obligatory for, the insertion of a *BsaX I* site at this
431 position. This unusual restriction site then provides for a potential
432 application of what is termed “Golden mutagenesis”, in which *any ten*
433 *nucleotides* can be inserted 3'- to the CUCC sequence, resulting in *any*
434 *three amino acids* being inserted between P5 (P681) and the conserved P1
435 arginine (R685). Golden mutagenesis is one application of “Golden Gate”
436 cloning (Engler and Marillonet, 2014) using “type II” restriction enzymes
437 (REs), a group that includes not only *BsaX I* (Tengs et al., 2004), but also

438 *Bsa* I and *BsmB* I, which have been extensively used in the design and
439 recovery of infectious clones of coronaviruses (Hou et al., 2020).

440

441 The use and application of type II REs was predicted and discussed by the
442 world's most accomplished coronavirus biologist several years ago, in
443 relation to potential biowarfare and bioterrorist activities (Baric, 2007).

444 There is some concern within the broader scientific community that similar
445 experiments might have led to the creation of a virus closely related to
446 SARS-CoV-2, a possibility that was foreseen by experts in biosecurity
447 many years earlier (Klotz and Sylvester, 2014). The summation of these
448 and other concerns about coronavirus engineering has led to calls by us
449 and others for the full disclosure of sequences, email communications and
450 laboratory notebooks, all as part of a detailed inquiry into the origins of the
451 virus (Relman, 2020, VanHelden et al., 2021; Harrison and Sachs, 2022a).

452

453 **Author contributions:** Both authors conceived the paper. NLH wrote the
454 first draft and both authors edited the final version. We are grateful to an
455 anonymous card-carrying virologist for helpful comments and advice.


456

457 **Competing Interests:** JDS is Chair of the Lancet COVID-19 Commission.
458 The authors declare no competing financial or scientific interests.

459

460 **Figures**

461 **Figure 1a**



462
463 **Figure 1b**

```

SARS-CoV-2 : ASYQTQTNSPRRARSVARSVASQS
SARS-CoV-1 : ASYHTV-----SLLRSTSQKS
Bat-TG13 : ASYQTQTN-----SRSRSVASQES
MERS-CoV : PSTLT-----PR-----SV-RSVPGEM
PangoL-CoV : ASYQTQTN-----S-----RSVSSKA
    
```


464
465 **Figure 1c**

	S1/S2	S2'
Human SARS-CoV BJ01	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Human SARS-CoV CUIK-W1	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Human SARS-CoV Tor2	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Human SARS-CoV Frankfurt-1	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Human SARS-CoV Urbani	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Civet SARS-CoV civet020	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Civet SARS-CoV SZ16	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Raccoon dog SARS-CoV A030	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
SARS-CoV-2	669 - GICASYQTQNSP RR ARSVA - 688	808 - DPKSPKRSFIED - 820
Pangolin CoV MP789	n/a - GICASYQTQNS-----RSV - n/a	n/a - DPKSPKRSFIED - n/a
Bat SARSr-CoV RaTG13	669 - GICASYQTQNS-----RSVA - 684	804 - DPKSPKRSFIED - 816
Bat SARSr-CoV LYRa11	659 - GICASYHTASL----RNTD - 674	794 - DPKSPKRSFIED - 806
Bat SARSr-CoV LYRa3	659 - GICASYHTASL----RNTG - 674	794 - DPKSPKRSFIED - 806
Bat SARSr-CoV ReSfC014	656 - GICASYHTVSSL----RSTS - 671	791 - DFLKPTKRSFIED - 803
Bat SARSr-CoV Re4084	656 - GICASYHTVSSL----RSTS - 671	791 - DFLKPTKRSFIED - 803
Bat SARSr-CoV WIV1	656 - GICASYHTVSSL----RSTS - 671	791 - DFLKPTKRSFIED - 803
Bat SARSr-CoV Re3367	656 - GICASYHTVSSL----RSTS - 671	791 - DFLKPTKRSFIED - 803
Bat SARSr-CoV Re7327	656 - GICASYHTVSSL----RSTS - 671	791 - DFLKPTKRSFIED - 803
Bat SARSr-CoV Re9401	656 - GICASYHTVSSL----RSTS - 671	791 - DFLKPTKRSFIED - 803
Bat SARSr-CoV Re4231	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Bat SARSr-CoV WIV16	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Bat SARSr-CoV Re4874	655 - GICASYHTVSSL----RSTS - 670	790 - DFLKPTKRSFIED - 802
Bat SARSr-CoV ZC45	646 - GICASYHTASL----RSTS - 661	781 - DPKSPKRSFIED - 793
Bat SARSr-CoV ZXC21	645 - GICASYHTASL----RSTG - 660	780 - DPKSPKRSFIED - 792
Bat SARSr-CoV Re4092	634 - GICASYHTASTL----RSGV - 649	769 - DPKSPKRSFIED - 781
Bat SARSr-CoV Re/OL2012	636 - GICASYHTASL----RSTG - 651	771 - DFLKPTKRSFIED - 783
Bat SARSr-CoV JYMC15	636 - GICASYHTASL----RSTG - 651	771 - DFLKPTKRSFIED - 783
Bat SARSr-CoV 16B0133	636 - GICASYHTASL----RSTG - 651	771 - DFLKPTKRSFIED - 783
Bat SARSr-CoV B15-21	636 - GICASYHTASL----RSTG - 651	771 - DFLKPTKRSFIED - 783
Bat SARSr-CoV YN2013	633 - GICASYHTASTL----RSIG - 648	768 - DPKSPKRSFIED - 780
Bat SARSr-CoV Anlong-103	633 - GICASYHTASTL----RSVG - 648	768 - DPKSPKRSFIED - 780
Bat SARSr-CoV Rp/Ghaanxi2011	640 - GICASYHTASVL----RSTG - 655	775 - DPKSPKRSFIED - 787
Bat SARSr-CoV Re/HuB2013	641 - GICASYHTASVL----RSTG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV YNLF/34C	641 - GICASYHTASVL----RSTG - 656	776 - DFLKPTKRSFIED - 788
Bat SARSr-CoV YNLF/31C	641 - GICASYHTASVL----RSTG - 656	776 - DFLKPTKRSFIED - 788
Bat SARSr-CoV Re1	641 - GICASYHTASHL----RSTG - 656	776 - DFLKPTKRSFIED - 788
Bat SARSr-CoV 273	641 - GICASYHTASHL----RSTG - 656	776 - DFLKPTKRSFIED - 788
Bat SARSr-CoV Re/SX2013	639 - GICASYHTASL----RSTG - 654	774 - DFLKPTKRSFIED - 786
Bat SARSr-CoV Re/HeB2013	641 - GICASYHTASL----RSTG - 656	776 - DFLKPTKRSFIED - 788
Bat SARSr-CoV Cp/Yunnan2011	641 - GICASYHTASL----RNTG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV Re672	641 - GICASYHTASTL----RSVG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV Re4255	641 - GICASYHTASTL----RSVG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV Re4081	641 - GICASYHTASTL----RSVG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV ReM1	641 - GICASYHTASVL----RSTG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV 279	641 - GICASYHTASVL----RSTG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV Re/GX2013	642 - GICASYHTASVL----RSTG - 657	777 - DPKSPKRSFIED - 789
Bat SARSr-CoV Re806	641 - GICASYHTASL----RSTG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV HKU3-1	642 - GICASYHTASVL----RSTG - 657	777 - DPKSPKRSFIED - 789
Bat SARSr-CoV Lonquuan-140	642 - GICASYHTASVL----RSTG - 657	777 - DPKSPKRSFIED - 789
Bat SARSr-CoV Rp3	641 - GICASYHTASTL----RSVG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV Re4247	642 - GICASYHTASTL----RSVG - 657	777 - DPKSPKRSFIED - 789
Bat SARSr-CoV Re4237	641 - GICASYHTASTL----RSVG - 656	776 - DPKSPKRSFIED - 788
Bat SARSr-CoV ReA6526	641 - GICASYHTASTL----RSVG - 656	777 - DPKSPKRSFIED - 789
Bat SARSr-CoV BtKY72/KEN	660 - GICAKFGS---D---KIRMG - 673	793 - DPKLLYRSFIED - 805
Bat SARSr-CoV BM48-31	658 - GICAKYTNVSSST---LVRSG - 674	794 - DPKAPKRSFIED - 806
	**** :	** * : *****

466


467

468 **Figure 2a**



469


470 **Figure 2b**



471

472 **Figure 3a**

473




474

475

476 **Figure 3b**


477



478

479 **Figure 4a**


480



481

482


483 **Figure 4b**



484

485


486 **Figure 5a**



487


488

489 **Figure 5b**




490

491 **Figure 5c**



492


493 **Figure 6a**



494
495


496 **Figure 6b**

497




498
499

500 **Figure 6c**



501
502


503 **Figure 6d**



504

505 **Figure 7a**

506




507

508

509 **Figure 7b**

510



511

512

513 **Figure 8a**


514

	CONSERVED REGION	VARIABLE REGION
SARS-CoV-2	G A G I C A S Y	Q T Q T N S P R R A R S V A S Q S I I
	ggt gca ggt ata tgc gct agt tat	cag act ca ^y act aat tct cct cgg cgg gca cgt agt gta gct agt caa tcc atc att
RaTG13	G A G I C A S Y	Q T Q T N S - - - - R S V A S Q S I I
	ggt gca gga ata tgc gcc agt tat	cag act caa act aat tca --- --- --- --- cgt agt gtg gcc agt caa tct att att

515

516

517 **Figure 8b**



518

519

520

521 **Figure Legends**

522

523 **Figure 1.** a. A schematic of the Spike protein of SARS-CoV-2, showing the
524 receptor binding domain and the two protease cleavage sites for furin and
525 TMPRSS2. From Keller et al. (2022). b. The amino acid sequences at the S1-S2
526 junction of the Spike proteins of five viruses, with the FCS of SARS-CoV-2
527 highlighted in red. From Coutard et al. (2020). c. Amino acid sequence alignments
528 around the S1-S2 junction of the Spike proteins of many members of the sub-genus
529 *Sarbecovirus*, with the FCS of SARS-CoV-2 highlighted in red. Adapted from
530 Hoffmann et al. (2020b).

531

532 **Figure 2.** a. The direct fusion pathway for SARS-CoV-2 entry is facilitated by
533 TMPRSS2. Adapted from Hoffmann and Pöhlmann (2021) b. The cell biology of
534 furin, showing its maturation in the Golgi, transport from the TGN to the plasma
535 membrane and subsequent uptake by endocytosis. Adapted from Thomas (2002).

536

537 **Figure 3.** a. A schematic of the generic extended furin cleavage site, illustrating
538 the core sequence flanked by two solvent-accessible regions. Adapted from Tian
539 (2009). b. The amino acid sequence of the extended FCS in the Spike protein of
540 SARS-CoV-2, labeled using the FCS numbering convention in Figure 3a.

541

542 **Figure 4.** The FCS of SARS-CoV-2 is an extended structure in a solvent-
543 accessible region of the Spike protein structure. a. A comparison between the
544 S1/S2 junction of SARS-CoV-1 and SARS-CoV-2. The insertion of PRRA extends
545 the loop structure relative to the analogous region of the SARS-CoV-1 Spike
546 protein, shown for comparison in these models. The peptide bond between R and S
547 is exposed to proteases. From Jaimes et al. (2020). b. A model of the extended
548 furin cleavage loop of SARS-CoV-2 from A668 to Y695, showing the highly
549 conserved *sarbecovirus* sequence C671-Y674 (CAS_Y), with the R682-R685
550 (RRAR) recognition sequence highlighted. From Arora et al. (2022).

551

552

553

554

555 **Figure 5.** a. The interaction between molecules of the Spike protein and furin (in
556 lilac), showing the location of the cleavage site protruding into the solvent. From
557 Venkadari (2020). b. The catalytic domain of furin (lilac) has several
558 electronegative residues (D228, N193, E230 etc..) that can make electrostatic
559 interactions with the furin cleavage site of the spike protein. From Venkadari
560 (2020) c. The extended FCS (green) is overlaid over the surface of the furin
561 catalytic domain (lilac). Positively charged R682, R683 and R685 interact with
562 furin while P681 projects away from the enzyme. The peptide bond between R685
563 and S686 is where the enzyme catalyzes the proteolysis of the Spike protein. From
564 Venkadari (2020).

565
566 **Figure 6.** a. The Spike protein of SARS-CoV-2 is subject to efficient proteolysis in
567 cells infected with the virus, while the SARS-CoV-1 Spike is not. Mutation of the
568 FCS (Sfur/mut) abolishes proteolysis. From Hoffmann et al. (2020b). b. The Spike
569 protein of SARS-CoV-2 is subject to proteolysis in cells infected with VSV
570 pseudovirus, while the SARS-CoV-1 Spike is not. Mutation of the FCS (Sfur/mut)
571 abolishes proteolysis. From Walls et al. (2020). c. The Spike protein of SARS-
572 CoV-2 is subject to proteolysis in cells infected with a pseudovirus, while the
573 SARS-CoV-1 Spike is not. Deletion of the FCS (-PRRA) abolishes proteolysis.
574 From Peacock et al. (2021).

575
576 **Figure 7.** a. Subtle differences in the structure of the Spike protein RBD from
577 SARS-CoV-2 (blue) and the related bat virus RaTG13 (pink), illustrating
578 unfavorable interactions between His 505 of RaTG13 and its receptor (green).
579 From Wrobel et al. (2020) b. The RBD of the SARS-CoV-2 virus binds to hACE2
580 with high (nanoMolar) affinity, while the RBD of the bat virus binds weakly to
581 ACE2, due in part to the lack of Phe 486, Glu 484 and 493 in the bat virus. From
582 Wrobel et al. (2020).

583
584 **Figure 8.** a. Sequence alignment between the Spike proteins of SARS-CoV-2 and
585 RaTG13 in the region of the FCS. The enumeration of the FCS begins at C, the
586 P15 residue in the conserved domain. Despite the sequence identity of the amino
587 acid sequence the divergent nucleotide sequence suggests that RaTG13 was neither
588 the immediate evolutionary precursor of SARS-CoV-2, nor a laboratory template.
589 From Deigin and Segreto (2021). b. A restriction enzyme site for *BsaX* I is located
590 within the extended FCS region and flanks the conserved 6 amino-acid sequence
591 QTQTNS, as well as the 4 amino-acid insert PRRA.

592
593
594

595 **References**

596

- 597 1. Anand P, Puranik A, Aravamudan M, Venkatakrisnan AJ,
598 Soundararajan V. SARS-CoV-2 strategically mimics proteolytic
599 activation of human ENaC. *Elife*. 2020 May 26;9:e58603.
- 600 2. Apaa T, Withers AJ, Staley C, Blanchard A, Bennett M, Bremner-
601 Harrison S, CHadwicj EA, Hailer F, Harrison SWR, Loose M,
602 Mathews F, Tarlinton R (2023) Sarbecoviruses of British Horseshoe
603 Bats; Sequence Variation and Epidemiology.
604 bioRxiv 2023.02.14.528476; doi: [https://doi.org/10.1101/2023.02.14.5](https://doi.org/10.1101/2023.02.14.528476)
605 28476.
- 606 3. Baric RS. (2007). Synthetic Viral Genomics. In: *Working Papers for*
607 *Synthetic Genomics: Risks and Benefits for Science and Society*, pp.
608 35-81. Garfinkel MS, Endy D, Epstein GL, Friedman RM, eds.
- 609 4. Belouzard, S., Chu, V. C. & Whittaker, G. R. (2009) Activation of the
610 SARS coronavirus spike protein via sequential proteolytic cleavage at
611 two distinct sites. *Proc. Natl Acad. Sci. USA* 106: 5871–5876.
- 612 5. Borucki MK, Allen JE, Chen-Harris H, Zemla A, Vanier G, Mabery S,
613 et al. (2013) The Role of Viral Population Diversity in Adaptation of
614 Bovine Coronavirus to New Host Environments. *PLoS ONE* 8(1):
615 e52752.
- 616 6. Bresnahan PA, Leduc R, Thomas L, Thorner J, Gibson HL, Brake AJ, Barr
617 PJ, Thomas G. (1990) Human fur gene encodes a yeast KEX2-like
618 endoprotease that cleaves pro-beta-NGF in vivo. *J Cell Biol.* 111:2851-
619 2859.
- 620 7. Chan YA, Zhan SH. (2022) The Emergence of the Spike Furin
621 Cleavage Site in SARS-CoV-2. *Mol Biol Evol.* 39: msab327.
- 622 8. Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N.G.,
623 and Decroly, E. (2020). The spike glycoprotein of the new
624 coronavirus 2019-nCoV contains a furin-like cleavage site absent in
625 CoV of the same clade. *Antiviral Res.* 176:104742.
- 626 9. Dahms SO, Arciniega M, Steinmetzer T, Huber R, Than ME. (2016)
627 Structure of the unliganded form of the proprotein convertase furin

- 628 suggests activation by a substrate-induced mechanism. Proc Natl
629 Acad Sci U S A. 113: 11196-11201.
- 630 10.Deigin Y, Segreto R (2021) SARS-CoV-2's claimed natural origin is
631 undermined by issues with genome sequences of its relative strains.
632 Coronavirus sequences RaTG13, MP789 and RmYN02 raise multiple
633 questions to be critically addressed by the scientific community.
634 BioEssays 43: 2100015.
- 635 11.Duckert P, Brunak S, Blom N (2004) Prediction of proprotein
636 convertase cleavage sites, Protein Engineering, Design and
637 Selection, 17: 107–112.
- 638 12.Essalmani R, Jain J, Susan-Resiga D, Andréo U, Evagelidis A,
639 Derbali RM, Huynh DN, Dallaire F, Laporte M, Delpal A, Sutto-Ortiz
640 P, Coutard B, Mapa C, Wilcoxon K, Decroly E, Nq Pham T, Cohen
641 ÉA, Seidah NG. (2022) Distinctive Roles of Furin and TMPRSS2 in
642 SARS-CoV-2 Infectivity. J Virol. 96:e0012822.
- 643 13.Engler C, Marillonnet S. (2014) Golden Gate cloning. Methods Mol
644 Biol. 1116:119-131.
- 645 14.Gallaher WR (2020) A palindromic RNA sequence as a common
646 breakpoint contributor to copy-choice recombination in SARS-COV-2
647 Arch. Virol., 165: 2341-2348.
- 648 15.Garry RF. (2022) SARS-CoV-2 furin cleavage site was not
649 engineered. Proceedings of the National Academy of Sciences of the
650 United States of America. 119: e2211107119.
- 651 16.Harrison NL, Sachs JD. (2022a) A call for an independent inquiry into
652 the origin of the SARS-CoV-2 virus. Proc Natl Acad Sci U S A. 119:
653 e2202769119.
- 654 17.Harrison NL, Sachs JD. (2022b) The origin of SARS-CoV-2 remains
655 unresolved. Proc Natl Acad Sci U S A. 119: e2215826119.
- 656 18.Haynes, W.A., Kamath, K., Bozekowski, J. *et al.* (2021) High-
657 resolution epitope mapping and characterization of SARS-CoV-2
658 antibodies in large cohorts of subjects with COVID-19. *Commun*
659 *Biol* 4, 1317.

- 660 19. Henrich S, Cameron A, Bourenkov GP, Kiefersauer R, Huber R,
661 Lindberg I, Bode W, Than ME. (2003) The crystal structure of the
662 proprotein processing proteinase furin explains its stringent
663 specificity. *Nat Struct Biol.* 10:520-526.
- 664 20. Hoffmann M, Kleine-Weber H, Pöhlmann S. (2020a) A Multibasic
665 Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for
666 Infection of Human Lung Cells. *Mol Cell.* 78:779-784.e5.
- 667 21. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T,
668 Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA,
669 Drosten C, Pöhlmann S. (2020b) SARS-CoV-2 Cell Entry Depends on
670 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease
671 Inhibitor. *Cell* 181:271-280.e8.
- 672 22. Hoffmann, M., Pöhlmann, S. (2021) How SARS-CoV-2 makes the
673 cut. *Nat Microbiol* **6**, 828–829.
- 674 23. Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-
675 Christoph A, Wertheim JO, Anthony SJ, Barclay WS, Boni MF,
676 Doherty PC, Farrar J, Geoghegan JL, Jiang X, Leibowitz JL, Neil
677 SJD, Skern T, Weiss SR, Worobey M, Andersen KG, Garry RF,
678 Rambaut A. The origins of SARS-CoV-2: A critical review. *Cell.* 2021
679 Sep 16;184(19):4848-4856.
- 680 24. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH
681 3rd, Kato T, Lee RE, Yount BL, Mascenik TM, Chen G, Olivier KN,
682 Ghio A, Tse LV, Leist SR, Gralinski LE, Schäfer A, Dang H, Gilmore
683 R, Nakano S, Sun L, Fulcher ML, Livraghi-Butrico A, Nicely NI,
684 Cameron M, Cameron C, Kelvin DJ, de Silva A, Margolis DM,
685 Markmann A, Bartelt L, Zumwalt R, Martinez FJ, Salvatore SP,
686 Borczuk A, Tata PR, Sontake V, Kimple A, Jaspers I, O'Neal WK,
687 Randell SH, Boucher RC, Baric RS. (2020) SARS-CoV-2 Reverse
688 Genetics Reveals a Variable Infection Gradient in the Respiratory
689 Tract. *Cell* 182:429-446.e14.
- 690 25. Hughey RP, Bruns JB, Kinlough CL, Harkleroad KL, Tong Q, Carattino
691 MD, Johnson JP, Stockand JD, Kleyman TR. (2004) Epithelial sodium

- 692 channels are activated by furin-dependent proteolysis. *J Biol Chem.*
693 279:18111-18114.
- 694 26. Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR (2020).
695 Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike
696 Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive
697 Activation Loop. *J Mol Biol.* 2020 May 1;432(10):3309-3325.
- 698 27. Johnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J,
699 Zhang X, Juelich T, Smith JK, Zhang L, Bopp N, Schindewolf C, Vu M,
700 Vanderheiden A, Swetnam D, Plante JA, Aguilar P, Plante KS, Lee B,
701 Weaver SC, Suthar MS, Routh AL, Ren P, Ku Z, An Z, Debbink K, Shi
702 PY, Freiberg AN, Menachery VD. (2021) Furin Cleavage Site Is Key to
703 SARS-CoV-2 Pathogenesis. *Nature*, 591:293-299.
- 704 28. Keller, C., Böttcher-Friebertshäuser, E. & Lohoff, M. (2022)
705 TMPRSS2, a novel host-directed drug target against SARS-CoV-
706 2. *Sig Transduct Target Ther* 7: 251.
- 707 29. Klimstra WB, Heidner HW, Johnston RE. (1999) The furin protease
708 cleavage recognition sequence of Sindbis virus PE2 can mediate virion
709 attachment to cell surface heparan sulfate. *J Virol.* 73:6299-6306.
- 710 30. Klotz LC, Sylvester EJ. (2014) The consequences of a lab escape of
711 a potential pandemic pathogen. *Front Public Health.* 2:116.
- 712 31. Kota P, Gentzsch M, Dang YL, Boucher RC, Stutts MJ. (2018) The N
713 terminus of α -ENaC mediates ENaC cleavage and activation by furin. *J*
714 *Gen Physiol.* 150:1179-1187.
- 715 32. Lerner S, Hvistendahl M. (2021) New details emerge about
716 coronavirus research at Chinese lab. *The Intercept* (6 September
717 2021). [https://theintercept.com/2021/09/06/new-details-emerge-](https://theintercept.com/2021/09/06/new-details-emerge-about-coronavirus-research-at-chinese-lab/)
718 [about-coronavirus-research-at-chinese-lab/](https://theintercept.com/2021/09/06/new-details-emerge-about-coronavirus-research-at-chinese-lab/). Accessed 22 February
719 2022.
- 720 33. Li, F., Li, W., Farzan, M., Harrison, S. C. (2005) Structural biology:
721 structure of SARS coronavirus spike receptor-binding domain
722 complexed with receptor. *Science* 309, 1864–1868.

- 723 34.Li W, Wicht O, van Kuppeveld FJ, He Q, Rottier PJ, Bosch BJ. (2015) A
724 Single Point Mutation Creating a Furin Cleavage Site in the Spike Protein
725 Renders Porcine Epidemic Diarrhea Coronavirus Trypsin Independent
726 for Cell Entry and Fusion. *J Virol.* 89:8077-81.
- 727 35.Menachery VD, Dinnon KH 3rd, Yount BL Jr, McAnarney ET,
728 Gralinski LE, Hale A, Graham RL, Scobey T, Anthony SJ, Wang L,
729 Graham B, Randell SH, Lipkin WI, Baric RS. (2020) Trypsin
730 Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *J*
731 *Virol.* 2020 94:e01774-19.
- 732 36.Menachery VD, Yount BL Jr, Sims AC, Debbink K, Agnihothram SS,
733 Gralinski LE, Graham RL, Scobey T, Plante JA, Royal SR,
734 Swanstrom J, Sheahan TP, Pickles RJ, Corti D, Randell SH,
735 Lanzavecchia A, Marasco WA, Baric RS. (2016) SARS-like WIV1-
736 CoV poised for human emergence. *Proc Natl Acad Sci U S A.*
737 113:3048-53.
- 738 37.Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A,
739 Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, Zepeda SK,
740 Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J,
741 Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T,
742 Mallery DL, Charles OJ; CITIID-NIHR BioResource COVID-19
743 Collaboration; Genotype to Phenotype Japan (G2P-Japan)
744 Consortium; Ecuador-COVID19 Consortium; Bowen JE, Joshi A,
745 Walls AC, Jackson L, Martin D, Smith KGC, Bradley J, Briggs JAG,
746 Choi J, Madisson E, Meyer KB, Mlcochova P, Ceron-Gutierrez L,
747 Doffinger R, Teichmann SA, Fisher AJ, Pizzuto MS, de Marco A,
748 Corti D, Hosmillo M, Lee JH, James LC, Thukral L, Veessler D, Sigal
749 A, Sampaziotis F, Goodfellow IG, Matheson NJ, Sato K, Gupta RK.
750 (2022) Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts
751 infectivity and fusogenicity. *Nature.* 603:706-714.
- 752 38.Millet, J. K. & Whittaker, G. R. (2014) Host cell entry of Middle East
753 respiratory syndrome coronavirus after two-step, furin-mediated
754 activation of the spike protein. *Proc. Natl Acad. Sci. USA* 111, 15214–
755 15219.

- 756 39.Millet, J. K. & Whittaker, G. R. (2015) Host cell proteases: critical
757 determinants of coronavirus tropism and pathogenesis. *Virus Res.*
758 202, 120–134.
- 759 40.Molloy SS, Thomas L, VanSlyke JK, Stenberg PE, Thomas G. (1994)
760 Intracellular trafficking and activation of the furin proprotein convertase:
761 localization to the TGN and recycling from the cell surface. *EMBO J.*
762 13:18-33.
- 763 41.Ou T, Mou H, Zhang L, Ojha A, Choe H, Farzan M. (2021)
764 Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is
765 attenuated by TMPRSS2. *PLoS Pathog.* 2021 17:e1009212.
- 766 42.Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC,
767 Kugathasan R, Penn R, Brown JC, Sanchez-David RY, Braga L,
768 Williamson MK, Hassard JA, Staller E, Hanley B, Osborn M, Giacca
769 M, Davidson AD, Matthews DA, Barclay WS. (2021a) The furin
770 cleavage site in the SARS-CoV-2 spike protein is required for
771 transmission in ferrets. *Nat Microbiol.* 6:899-909.
- 772 43.Peacock TP, Sheppard CM, Brown JC, Goonawardane N, Zhou J,
773 Whiteley M, et al. (2021b) The SARS-CoV-2 variants associated with
774 infections in India, B.1.617, show enhanced spike cleavage by furin.
775 *bioRxiv.* 2021:2021.05.28.446163.
- 776 44.Relman DA. (2020) To stop the next pandemic, we need to unravel
777 the origins of COVID-19. *Proc Natl Acad Sci U S A.* 117:29246-
778 29248.
- 779 45.Sander AL, Moreira-Soto A., Yordanov S. *et al.* (2022) Genomic
780 determinants of Furin cleavage in diverse European SARS-related bat
781 coronaviruses. *Commun Biol* 5: 491.
- 782 46.Schrauwen EJA, Bestebroer TM, Munster VJ, de Wit E, Herfst S,
783 Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM. (2011) Insertion
784 of a multibasic cleavage site in the haemagglutinin of human
785 influenza H3N2 virus does not increase pathogenicity in ferrets. *J*
786 *Gen Virol.* 2011 92:1410-1415.

- 787 47. Segreto R, Deigin Y. The genetic structure of SARS-CoV-2 does not
788 rule out a laboratory origin: SARS-COV-2 chimeric structure and furin
789 cleavage site might be the result of genetic manipulation. *Bioessays*.
790 2021 Mar;43(3):e2000240.
- 791 48. Seidah NG, Day R, Marcinkiewicz M, Chrétien M. (1998) Precursor
792 convertases: an evolutionary ancient, cell-specific, combinatorial
793 mechanism yielding diverse bioactive peptides and proteins. *Ann N Y*
794 *Acad Sci*. 839:9-24.
- 795 49. Seidah NG & Prat A. (2012) The biology and therapeutic targeting of
796 the proprotein convertases. *Nature Reviews Drug Discovery*, 11: 367-
797 383.
- 798 50. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A,
799 Li F. (2020) Structural basis of receptor recognition by SARS-CoV-2.
800 *Nature*. 581:221-224.
- 801 51. Sirotkin K, Sirotkin D. Might SARS-CoV-2 Have Arisen via Serial
802 Passage through an Animal Host or Cell Culture?: A potential
803 explanation for much of the novel coronavirus' distinctive genome.
804 *Bioessays*. 2020 Oct;42(10):e2000091.
- 805 52. Temmam S, Vongphayloth K, Salazar EB, Munier S, Bonomi M,
806 Regnault B, Douangboubpha B, Karami Y, Chrétien D, Sanamxay D
807 et al (2022) Bat coronaviruses related to SARS-CoV-2 and infectious
808 for human cells. *Nature* 604: 330-336
- 809 53. Temmam S, Montagutelli X, Herate C, Donati F, Regnault B, Attia M,
810 Baquero Salazar E, Chretien D, Conquet L, Jouvion G, Pipoli Da
811 Fonseca J, Cokelaer T, Amara F, Relouzat F, Naninck T, Lemaitre J,
812 Derreudre-Bosquet N, Pascal Q, Bonomi M, Bigot T, Munier S, Rey
813 FA, Le Grand R, van der Werf S, Eloit M. (2023) SARS-CoV-2-related
814 bat virus behavior in human-relevant models sheds light on the origin
815 of COVID-19. *EMBO Rep*. 6:e56055.
- 816 54. Tengs T, LaFramboise T, Den RB, Hayes DN, Zhang J, DebRoy S,
817 Gentleman RC, O'Neill K, Birren B, Meyerson M. (2004) Genomic
818 representations using concatenates of Type IIB restriction
819 endonuclease digestion fragments. *Nucleic Acids Res*. 32:e121.

- 820 55.Thomas G. (2002) Furin at the cutting edge: from protein traffic to
821 embryogenesis and disease. *Nat Rev Mol Cell Biol.* 3:753-766
- 822 56.Tian S. (2009) A 20 residues motif delineates the furin cleavage site
823 and its physical properties may influence viral fusion. *Biochemistry*
824 *Insights*; 2. doi:10.4137/BCI.S2049.
- 825 57.Van Helden J, Butler CD, Achaz G, Canard B, Casane D, Claverie
826 JM, Colombo F, Courtier V, Ebright RH, Graner F, Leitenberg M,
827 Morand S, Petrovsky N, Segreto R, Decroly E, Halloy J. (2021) An
828 appeal for an objective, open, and transparent scientific debate about
829 the origin of SARS-CoV-2. *Lancet.* 398:1402-1404.
- 830 58.Venkadari N (2020). Structure of Furin Protease Binding to SARS-
831 CoV-2 Spike Glycoprotein and Implications for Potential Targets and
832 Virulence. *The Journal of Physical Chemistry Letters* 11: 6655-6663.
- 833 59.Vu MN, Lokugamage KG, Plante JA, Scharon D, Bailey AO, Sotcheff
834 S, Swetnam DM, Johnson BA, Schindewolf C, Alvarado RE,
835 Crocquet-Valdes PA, Debbink K, Weaver SC, Walker DH, Russell
836 WK, Routh AL, Plante KS, Menachery VD. (2022) QTQTN motif
837 upstream of the furin-cleavage site plays a key role in SARS-CoV-2
838 infection and pathogenesis. *Proc Natl Acad Sci U S A.* 119:
839 e2205690119.
- 840 60.Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D.
841 (2020) Structure, Function, and Antigenicity of the SARS-CoV-2
842 Spike Glycoprotein. *Cell.* 181:281-292.e6
- 843 61.Watanabe R, Matsuyama S, Shirato K, Maejima M, Fukushi S, et al.
844 (2008) Entry from the Cell Surface of Severe Acute Respiratory
845 Syndrome Coronavirus with Cleaved S Protein as Revealed by
846 Pseudotype Virus Bearing Cleaved S Protein. *J Virol* 82: 11985–
847 11991.
- 848 62.Winstone H, Lista MJ, Reid AC, Bouton C, Pickering S, Galao RP,
849 Kerridge C, Doores KJ, Swanson CM, Neil SJD. (2021) The
850 Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral
851 Sensitivity to Type I Interferon and IFITM2. *J Virol.* 95:e02422-20.

- 852 63. Wolf KA, Kwan JC, Kamil JP. (2022) Structural Dynamics and
853 Molecular Evolution of the SARS-CoV-2 Spike Protein. *mBio*.
854 13:e0203021.
- 855 64. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O,
856 Graham BS, McLellan JS. (2020) Cryo-EM structure of the 2019-nCoV
857 spike in the prefusion conformation. *Science*. 367:1260-1263.
- 858 65. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB,
859 Skehel JJ, Gamblin SJ. (2020) SARS-CoV-2 and bat RaTG13 spike
860 glycoprotein structures inform on virus evolution and furin-cleavage
861 effects. *Nat Struct Mol Biol*. 27:763-767.
- 862 66. Wu Y, Zhao S (2021) Furin cleavage sites naturally occur in
863 coronaviruses. *Stem Cell Research*, 50, 102115.
- 864 67. Zimmer G, Conzelmann KK, Herrler G. (2002) Cleavage at the furin
865 consensus sequence RAR/KR(109) and presence of the intervening
866 peptide of the respiratory syncytial virus fusion protein are
867 dispensable for virus replication in cell culture. *J Virol*. 76:9218-9224.
- 868
869